Establishing patients’ baseline for parameters such as spirometry, blood work, vital signs, weight, and BMI, as well as clinical status for CF-related comorbidities is essential in monitoring for a number of the described AE following initiation of CFTR modulators. The gene discussed is CFTR; the disease is cystic fibrosis.